Association Between Diabetes and Mortality Among Adult Patients Hospitalized With COVID-19: A Cohort Study of Hospitalized Adults in Ontario, Canada, and Copenhagen, Denmark.

COVID-19 COVID-19 mortality COVID-19 severity care processes comorbidities comorbidités diabetes diabète gravité de la COVID-19 mortalité liée à la COVID-19 processus de soins

Journal

Canadian journal of diabetes
ISSN: 2352-3840
Titre abrégé: Can J Diabetes
Pays: Canada
ID NLM: 101148810

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 13 07 2022
revised: 09 02 2023
accepted: 17 02 2023
medline: 19 6 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Diabetes has been reported to be associated with an increased risk of death among patients with COVID-19. However, the available studies lack detail on COVID-19 illness severity and measurement of relevant comorbidities. We conducted a multicentre, retrospective cohort study of patients 18 years of age and older who were hospitalized with COVID-19 between January 1, 2020, and November 30, 2020, in Ontario, Canada, and Copenhagen, Denmark. Chart abstraction emphasizing comorbidities and disease severity was performed by trained research personnel. The association between diabetes and death was measured using Poisson regression. The main outcome measure was in-hospital 30-day risk of death. Our study included 1,133 hospitalized patients with COVID-19 in Ontario and 305 in Denmark, of whom 405 and 75 patients, respectively, had pre-existing diabetes. In both Ontario and Denmark, patients with diabetes were more likely to be older; have chronic kidney disease, cardiovascular disease, and higher troponin levels; and be receiving antibiotics, when compared with adults without diabetes. In Ontario, 24% (n=96) of adults with diabetes died compared with 15% (n=109) of adults without diabetes. In Denmark, 16% (n=12) of adults with diabetes died in hospital compared with 13% (n=29) of those without diabetes. In Ontario, the crude mortality ratio among patients with diabetes was 1.60 (95% confidence interval [CI], 1.24 to 2.07) and in the adjusted regression model it was 1.19 (95% CI, 0.86 to 1.66). In Denmark, the crude mortality ratio among patients with diabetes was 1.27 (95% CI, 0.68 to 2.36) and in the adjusted model it was 0.87 (95% CI, 0.49 to 1.54). Meta-analysis of the 2 rate ratios from each region resulted in a crude mortality ratio of 1.55 (95% CI, 1.22 to 1.96) and an adjusted mortality ratio of 1.11 (95% CI, 0.84 to 1.47). The presence of diabetes was not strongly associated with in-hospital COVID-19 mortality independent of illness severity and other comorbidities.

Identifiants

pubmed: 37074240
pii: S1499-2671(23)00038-2
doi: 10.1016/j.jcjd.2023.02.005
pmc: PMC9946865
pii:
doi:

Types de publication

Meta-Analysis Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-358

Informations de copyright

Copyright © 2023 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Nat Rev Endocrinol. 2021 Jan;17(1):11-30
pubmed: 33188364
Endocrinol Diabetes Metab. 2020 Aug 14;4(1):e00176
pubmed: 32904932
JAMA Netw Open. 2021 Jan 4;4(1):e2036462
pubmed: 33512520
Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-792
pubmed: 32687793
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
BMJ. 2022 Mar 23;376:e068585
pubmed: 35321918
Diabetes Care. 2021 Jan;44(1):50-57
pubmed: 33097559
CMAJ. 2021 Mar 22;193(12):E410-E418
pubmed: 33568436
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Clin Hypertens (Greenwich). 2021 Feb;23(2):218-231
pubmed: 33369066
Endocr Rev. 2020 Jun 1;41(3):
pubmed: 32294179
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
Lancet. 2021 Feb 13;397(10274):605-612
pubmed: 33545096
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471

Auteurs

Orly Bogler (O)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Afsaneh Raissi (A)

Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Michael Colacci (M)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada.

Andrea Beaman (A)

Trillium Health Partners, Mississauga, Ontario, Canada.

Tor Biering-Sørensen (T)

Department of Cardiology, University of Copenhagen, Copenhagen, Denmark.

Alex Cressman (A)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada.

Allan Detsky (A)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Alexi Gosset (A)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Mats Højbjerg Lassen (MH)

Department of Cardiology, University of Copenhagen, Copenhagen, Denmark.

Chris Kandel (C)

Michael Garron Hospital, Toronto, Ontario, Canada.

Yaariv Khaykin (Y)

Department of Medicine, Southlake Regional Health Centre, Newmarket, Ontario, Canada.

David Barbosa (D)

Department of Medicine, Southlake Regional Health Centre, Newmarket, Ontario, Canada.

Lauren Lapointe-Shaw (L)

Department of Medicine, University Health Network, Toronto, Ontario, Canada.

Derek R MacFadden (DR)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Alexander Pearson (A)

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Bruce A Perkins (BA)

Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Kenneth J Rothman (KJ)

Department of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, United States.

Kristoffer Grundtvig Skaarup (KG)

Department of Cardiology, University of Copenhagen, Copenhagen, Denmark.

Rachael Weagle (R)

Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Chris Yarnell (C)

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.

Michelle Sholzberg (M)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.

Benazir Hodzic-Santor (B)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Erik Lovblom (E)

Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Jonathan Zipursky (J)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada.

Kieran L Quinn (KL)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Interdepartmental Division of Palliative Care, Sinai Health System and University of Toronto, Toronto, Ontario, Canada.

Mike Fralick (M)

Department of Medicine, University of Toronto, Temerty Faculty of Medicine, Toronto, Ontario, Canada; Sinai Health System, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: mike.fralick@mail.utoronto.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH